Why Investors Are Fleeing Moderna (MRNA)

This afternoon we watched Moderna drop -9.2% to a price of $124.96 per share. The Large-Cap Biotechnology company is now trading -13.91% below its average target price of $145.15. Analysts have set target prices ranging from $62.0 to $310.0 per share for Moderna, and have given the stock an average rating of hold.

Moderna has an average level of shares sold short, at 6.9% of its total share float. The stock's short ratio (also called days to cover) is 4.05. The company's insiders own 9.57% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 73.4% of Moderna's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Moderna

Date Reported Holder Percentage Shares Value
2024-03-31 Baillie Gifford and Company 12% 44,655,817 $5,580,190,851
2024-03-31 Vanguard Group Inc 10% 39,036,872 $4,878,047,489
2024-03-31 Blackrock Inc. 7% 25,395,878 $3,173,468,891
2024-03-31 State Street Corporation 4% 14,452,035 $1,805,926,280
2024-03-31 FMR, LLC 4% 13,599,837 $1,699,435,619
2024-03-31 Flagship Pioneering Inc. 3% 9,666,038 $1,207,868,099
2024-03-31 Theleme Partners LLP 2% 7,321,797 $914,931,746
2024-03-31 Geode Capital Management, LLC 2% 6,750,479 $843,539,849
2024-03-31 Wellington Management Group, LLP 1% 5,604,703 $700,363,681
2024-03-31 Morgan Stanley 1% 5,493,965 $686,525,861
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.